Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 5/20 | 0.44 |
| ▸ | HTR2A | P28223 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 11/20 | 0.40 |
| ▸ | HTR2B | P41595 | 3/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.38 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4306200 | 0.86 | HTR2C (0.49) | HTR2CHTR2AHTR2BCHRNB2CHRNB4 | |
| SCHEMBL25052839 | 0.86 | HTR2C (0.49) | HTR2CHTR2AHTR2BCHRNB2CHRNB4 | |
| SCHEMBL4233662 | 0.80 | HTR2C (0.38) | HTR2CHTR2ATACR1HTR2B | |
| SCHEMBL5734703 | 0.76 | KDM4E (0.41) | HTR2CHTR2B | |
| SCHEMBL4300202 | 0.74 | MAOB (0.45) | — | |
| SCHEMBL11034439 | 0.73 | HTR2C (0.49) | HTR2CHTR2AHTR2B | |
| SCHEMBL6026785 | 0.69 | ADRB1 (0.43) | HTR2CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL21725482 | 0.69 | HTR2C (0.58) | HTR2C | |
| SCHEMBL23250102 | 0.69 | TAAR1 (0.45) | HTR2CHTR2AHTR2B | |
| SCHEMBL24005470 | 0.69 | TAAR1 (0.45) | HTR2CHTR2AHTR2BCHRNB4CHRNA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795611-B2 | Method of treatment using substituted imidazo[1,2b]pyridazine compounds | ARRAY BIOPHARMA, INC. (US) | 2017-10-24 | — | — | US | disclosed |
| US-20170112849-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | ARRAY BIOPHARMA, INC. | 2017-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170112849-A1 | Method of Treatment Using Substituted Imidazo[1,2b]Pyridazine Compounds | COL2A1, COL1A1, IFNAR1 | HTR2C 715/4885HTR2A 782/4885TACR1 1510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.